Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Expansion in clinical trial eligibility requested by ASCO

Friends of Cancer and ASCO letter to the FDA

Key clinical point: ASCO and Friends of Cancer have submitted draft recommendations to the FDA for expanding cancer clinical trial participation.

Major finding: The organizations recommend addressing minimum age requirements, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.

Data source: Draft guidance produced by ASCO and Friends of Cancer Research and submitted to the FDA.

Disclosures: Individual members of the working groups were not listed and conflicts of interest were not disclosed.

Read the article.

Citation:

Friends of Cancer and ASCO letter to the FDA.

This Week's Must Reads

RNA expression offers potential biomarker in hemophilia A, Niloofar N et al. Hematology. 2019;24(1):255-62

Caplacizumab speeds platelet normalization, Scully M et al. N Engl J Med. 2019 Jan 9. doi: 10.1056/NEJMoa1806311

Remote area of Canada provides pool for genetic research, Scully M-F et al. Transfus Apher Sci. 2018 Dec;57(6):713-6

Can web tools replace pharmacokinetic analysis in hemophilia A?, Nagao A et al. Thromb Res. 2019 Jan;173:79-84

BSH issues recommendations for glucocorticoid use in ITP, Hill QA et al. Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15735

Must Reads in Business of Medicine

For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

CMS wants to flatten E/M payments, CMS proposed rule, CMS-1693-P

Lay health workers can assist with end-of-life care, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.